# Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma

> **NCT00072358** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 291 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **BIOLOGICAL:** anti-GD2 murine IgG3 monoclonal antibody 3F8
- **BIOLOGICAL:** anti-GD2 murine IgG3 monoclonal antibody 3F8

## Key facts

- **NCT ID:** NCT00072358
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2021-01-15
- **Final completion:** 2021-01-15
- **Target enrollment:** 291 (ACTUAL)
- **Last updated:** 2022-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00072358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00072358, "Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00072358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*